Home › Therapeutic areas › Oncology › Melanoma
Melanoma (16 companies)
Companies with an active program in Melanoma.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| BCTX | BriaCell Therapeutics | Oncology | 1 | Phase 3 | $30.7M | 8 |
| CMPX | Compass Therapeutics | Oncology | 1 | Phase 2 | $109M | 15 |
| CTMX | CytomX Therapeutics | Oncology | 1 | Phase 1 | $423M | 7 |
| EIKN | Eikon Therapeutics | Oncology | 1 | Phase 2 | $279M | 13 |
| EXEL | Exelixis | CardiovascularOncology | 1 | Approved | $16.7B | 23 |
| IDYA | IDEAYA Biosciences | Oncology | 2 | NDA Submitted | $2.65B | 15 |
| IMTX | Immatics | Oncology | 3 | Phase 3 | $958M | 8 |
| IMRX | Immuneering | Oncology | 1 | Phase 3 | $224M | 5 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 4 | Approved | $1.44B | 12 |
| MDNAF | Medicenna Therapeutics | Oncology | 1 | Phase 2 | $14.8M | 10 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 1 | Phase 3 | $1.56B | 13 |
| CATX | Perspective Therapeutics | Oncology | 1 | Phase 1 | $104M | 5 |
| PHIO | Phio Pharmaceuticals | Oncology | 1 | Phase 1 | $8.6M | 4 |
| RLAY | Relay Therapeutics | DermatologyOncology Rare | 1 | Approved | $3.64B | 4 |
| REPL | Replimune Group | Oncology | 2 | Approved | $1.87B | 5 |
| HURA | TuHURA Biosciences | Oncology | 1 | Phase 3 | $92.1M | 4 |
No companies match.